Healthcare Sector

LLY

Market Tracker

$1,000.15
-8.24
(-0.82%)
6:40 pm
Next Earnings: (est.) 08/08/23 12:00 am
  • LLY (Selected)

    Eli Lilly and Company
  • LLYVA

  • LLYVK

  • LLYX

LLY Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

LLY Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

LLY Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

LLY Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

LLY Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

LLY Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
04/10/2026 PUT $900.00 1,010 +1,001 +11,122.22%
03/27/2026 PUT $920.00 1,075 +977 +996.94%
04/17/2026 PUT $400.00 2,065 +916 +79.72%
03/13/2026 CALL $1,050.00 902 +626 +226.81%
04/17/2026 PUT $380.00 828 +587 +243.57%
03/13/2026 CALL $1,080.00 586 +465 +384.30%
12/18/2026 CALL $1,500.00 127 -64 -33.51%
03/13/2026 PUT $975.00 232 -82 -26.11%
06/18/2026 CALL $1,300.00 725 -84 -10.38%
03/13/2026 PUT $995.00 107 -95 -47.03%
03/20/2026 PUT $430.00 414 -97 -18.98%
03/13/2026 CALL $1,120.00 155 -206 -57.06%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

LLY Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 2.74% 26M 11.45B
Vanguard 500 Index Fund 1.92% 18.23M 8.03B
Vanguard/Primecap Fund 1.56% 14.85M 6.54B
Fidelity 500 Index Fund 0.91% 8.65M 3.81B
SPDR S&P 500 ETF Trust 0.90% 8.54M 3.76B
Vanguard Specialized-Health Care Fund 0.80% 7.64M 3.37B
iShares Core S&P 500 ETF 0.74% 7.04M 3.1B
Washington Mutual Investors Fund 0.73% 6.95M 3.06B
Growth Fund Of America Inc 0.71% 6.7M 2.95B
Select Sector SPDR Fund-Health Care 0.67% 6.41M 2.82B

LLY News

  • 2 Healthcare Stocks That Are Too Cheap to Ignore

    03/10 12:23 pm

    The Motley Fool

    Read more
  • Roche's Breast Cancer Drug Falls Short In Phase 3 Study

    03/09 08:09 am

    Benzinga

    Read more
  • Better Weight Loss Stock: Novo Nordisk Vs. Amgen

    03/08 02:30 pm

    The Motley Fool

    Read more
  • 1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid

    03/08 01:30 pm

    The Motley Fool

    Read more
  • Where Will Eli Lilly Stock Be in 10 Years?

    03/07 12:15 pm

    The Motley Fool

    Read more
  • Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

    03/06 07:05 pm

    The Motley Fool

    Read more
  • China Clears Weight-Loss Shot As Pfizer Enters Crowded Market

    03/06 09:14 am

    Benzinga

    Read more
  • Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

    03/06 07:47 am

    Benzinga

    Read more
  • Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors

    03/05 05:05 pm

    The Motley Fool

    Read more
  • GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities

    03/04 06:48 am

    GlobeNewswire Inc.

    Read more
  • 2 Top Growth Stocks to Buy in the First Half of 2026

    03/03 08:15 pm

    The Motley Fool

    Read more
  • Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

    03/03 04:14 pm

    The Motley Fool

    Read more
  • Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree

    03/02 02:15 pm

    The Motley Fool

    Read more
  • Antibiotics Market - 4.07% CAGR Forecast for 2026-2031 as Antimicrobial Innovation Strengthens Demand, Says Mordor Intelligence

    03/02 05:59 am

    GlobeNewswire Inc.

    Read more
  • The New Magnificent Stocks to Own in 2026

    02/27 01:06 pm

    Investing.com

    Read more
  • Nvidia Hit by Profit Taking but $300 Target Still in Sight

    02/26 04:37 pm

    Investing.com

    Read more
  • PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

    02/26 02:35 pm

    GlobeNewswire Inc.

    Read more
  • Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore

    02/26 08:17 am

    The Motley Fool

    Read more
  • The Next Magnificent 7? 4 Large Caps Gaining Momentum

    02/26 03:05 am

    Investing.com

    Read more
  • Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.

    02/25 03:15 pm

    The Motley Fool

    Read more
  • Ozempic Price War - Novo Nordisk Slashes Prices By 50%

    02/25 10:13 am

    Benzinga

    Read more
  • 5 Stocks With 20%+ EPS Growth and Strong Balance Sheets

    02/25 03:53 am

    Investing.com

    Read more
  • Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?

    02/25 01:30 am

    The Motley Fool

    Read more
  • Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight

    02/24 07:00 am

    Benzinga

    Read more
  • Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

    02/23 09:30 pm

    The Motley Fool

    Read more
  • Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short

    02/23 06:21 pm

    The Motley Fool

    Read more
  • 1 Reason I'd Buy Veeva Systems Stock and Never Sell

    02/23 05:37 pm

    The Motley Fool

    Read more
  • Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

    02/23 03:29 pm

    Benzinga

    Read more
  • Novo Nordisk Trades at 11x Earnings as GLP-1 Reset Tests Long-Term Thesis

    02/23 02:22 pm

    Investing.com

    Read more
  • Novo Nordisk's Loss Is Eli Lilly's Gain

    02/23 12:42 pm

    Benzinga

    Read more
  • Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms

    02/23 12:35 pm

    Benzinga

    Read more
  • Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash

    02/23 11:30 am

    The Motley Fool

    Read more
  • 1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock

    02/23 08:18 am

    The Motley Fool

    Read more
  • Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's

    02/23 06:31 am

    Benzinga

    Read more
  • 3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds

    02/23 06:10 am

    The Motley Fool

    Read more
  • Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?

    02/22 07:30 pm

    The Motley Fool

    Read more
  • The Stock Market Just Did This for the First Time in Nearly a Year. History is Strikingly Clear About What Happens Next.

    02/21 05:15 am

    The Motley Fool

    Read more
  • Novo Nordisk Stock Investors Just Got Great News From Eli Lilly

    02/20 09:15 pm

    The Motley Fool

    Read more
  • Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

    02/20 02:15 pm

    The Motley Fool

    Read more
  • Eli Lilly Breaks New Ground In Crohn's Disease Treatment

    02/20 08:23 am

    Benzinga

    Read more
  • Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - Oral Formulations and Long-Acting Peptides Accelerate Next-Gen Obesity and Diabetes Therapies

    02/20 06:53 am

    GlobeNewswire Inc.

    Read more
  • ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

    02/20 01:02 am

    The Motley Fool

    Read more
  • Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo

    02/18 01:51 pm

    Benzinga

    Read more
  • Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - Opportunities in Surge in Merger & Acquisitions, Increasing R&D Investments

    02/18 08:00 am

    GlobeNewswire Inc.

    Read more
  • Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider

    02/18 06:55 am

    GlobeNewswire Inc.

    Read more
  • 2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?

    02/17 09:15 am

    The Motley Fool

    Read more
  • Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients

    02/17 07:42 am

    Benzinga

    Read more
  • Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

    02/16 09:00 am

    GlobeNewswire Inc.

    Read more
  • What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?

    02/14 03:25 pm

    The Motley Fool

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: